Dr. Adi Zuloff-Shani PhD., Clearmind’s chief executive officer will discuss its Nasdaq IPO with David Huberman, Capital Markets Shareholder at Greenberg Traurig law firm Tel Aviv, Israel / Vancouver, Canada, Feb. 14, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company”), a biotech company focused on discovery and development of novel…


Previous articleSilo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
Next articleDelix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability